Oil and gas majors such as ExxonMobil and Shell have sent staff to the summit, as have pharmaceutical giants such as GSK, and the multinational mining ... Compared to climate summits, where corporate ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), following a string of exits by companies including Pfizer, UCB, WuXi AppTec and ...

Bearish flow noted in GSK (GSK) Pharma with 2,296 puts trading, or 1.2x expected. Most active are May-25 30 puts and Dec-24 38 calls, with total volume in those strikes near 2,500 contracts.

Legalcategory GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 bln October 9, 2024 Healthcare & Pharmaceuticalscategory GSK, Pfizer RSV vaccine sales fall in US as millions fewer ...

GSK plans to invest $800 million in its East Donegal Township vaccine packaging facility over the next four years in an expansion project that would add research and manufacturing capabilities ...

THE ARM FOR THE LANCASTER COUNTY ECONOMY. THIS IS FOR GSK, THE LARGEST INVESTMENT IN MANUFACTURING WE’VE EVER DONE IN THE UNITED STATES. THE $800 MILLION WILL BE USED TO EXPAND GSK’S MARIETTA ...

GlaxoSmithKline (GSK) has firmly acquired the number one position in the Egyptian pharmaceutical market since 2009 and is likely to maintain the grip at least until the end of 2011. GSK’s ...

Preliminary results from two trials showed that GSK’s respiratory syncytial virus (RSV) vaccine Arexvy has potential in younger adults with certain risk factors, potentially positioning the shot ...

Researchers from the Center for Regenerative Medicine (CReM) at Boston University and Boston Medical Center (BMC) have announced a new collaboration with the global biopharma company GSK to ...

This time, we have GSK (GSK) "GSK" filing a lawsuit against Moderna (NASDAQ:MRNA) accusing them of patent infringement on their lipid nanoparticle (LNP) technology, which is used in mRNA therapeutics.

The market expects GSK (GSK) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is ...